Effective Control of Synchronous Male Breast and Prostate Cancer with Androgen Deprivation Therapy: A Case Report Authors: Megumi Furukawa, Naomi Gondo, Reiko Mitsueda, Akiko Arimura, Yoshitaka Fujiki, Junko Kawano, Shuichi Kanemitsu, Megumi Teraoka, Yasuyo Ohi, Yoshiaki Rai, Yoshiaki Sagara, Yasuaki Sagara, Shinji Ohno Published: 2026 ABSTRACT ABSTRACTINTRODUCTIONMale breast cancer (BC) is a rare disease, accounting for less than 1% of all BCs, and its synchronous occurrence with prostate cancer (PC) is exceedingly rare. Male BC is generally managed according to treatment strategies established for female BC; however, the role of androgen receptor (AR) signaling and androgen deprivation therapy (ADT) in male BC remains unclear. In particular, the optimal treatment strategy for patients with synchronous male BC and PC has not been established, and it is unknown whether ADT for PC exerts therapeutic effects on AR-positive male BC.CASE PRESENTATIONA 74-year-old Japanese man was diagnosed with synchronous estrogen receptor (ER)-positive, AR-positive, luminal A-like male BC (cStage IIA) and metastatic PC (Stage IV). Given that the prognosis was primarily determined by metastatic PC, ADT consisting of a gonadotropin-releasing hormone antagonist and an AR antagonist was initiated prior to breast surgery. Notably, marked tumor regression was observed in the breast lesion during ADT. Subsequent mastectomy with sentinel lymph node biopsy revealed ypT1c pN0 disease.CONCLUSIONSThis case represents a rare clinical scenario in which standard ADT successfully controlled both metastatic PC and operable ER- and AR-positive male BC without upfront breast surgery. This case suggests that ADT may represent a potential initial therapeutic option for synchronous malignancies, particularly in patients in whom surgery is not feasible or can be deferred. Abbreviations androgen deprivation therapy androgen receptor breast cancer ductal carcinoma in situ estrogen receptor gonadotropin-releasing hormone luteinizing hormone-releasing hormone prostate cancer progesterone receptor prostate-specific antigen INTRODUCTION Male BC is a rare disease, accounting for less than 1% of all BCs.1,2) The synchronous occurrence of male BC and PC is extremely uncommon, and no standardized treatment strategies have been established due to the limited number of reported cases. Herein, we report a case of synchronous cStage IIA male BC and Stage IV PC in which ADT effectively controlled both malignancies. In previously reported cases of synchronous male BC and PC, operable BC has typically been managed surgically before the initiation of ADT for PC. In contrast, our case demonstrated effective control of operable BC with ADT without upfront breast surgery. This represents one of the few reported cases in which ADT successfully controlled both metastatic PC and operable ER-positive and AR-positive male BC in a synchronous setting. This case highlights the potential role of ADT as an initial treatment strategy in synchronous male BC and PC. CASE PRESENTATION A 74-year-old Japanese man presented to our hospital with a palpable mass in the left breast. -Past medical history: Nine years earlier, he had undergone surgery for rectal cancer without adjuvant therapy, and no recurrence had been observed until the present diagnosis of BC.-Comorbidities: Type 2 diabetes mellitus and hypertension.-Family history: Unremarkable, with no family history of breast, ovarian, or pancreatic cancer.-Clinical and imaging findings: Physical examination revealed a mass in the left breast E quadrant, fixed to the overlying skin. -Past medical history: Nine years earlier, he had undergone surgery for rectal cancer without adjuvant therapy, and no recurrence had been observed until the present diagnosis of BC. Past medical history: Nine years earlier, he had undergone surgery for rectal cancer without adjuvant therapy, and no recurrence had been observed until the present diagnosis of BC. -Comorbidities: Type 2 diabetes mellitus and hypertension. Comorbidities: Type 2 diabetes mellitus and hypertension. -Family history: Unremarkable, with no family history of breast, ovarian, or pancreatic cancer. Family history: Unremarkable, with no family history of breast, ovarian, or pancreatic cancer. -Clinical and imaging findings: Physical examination revealed a mass in the left breast E quadrant, fixed to the overlying skin. Clinical and imaging findings: Physical examination revealed a mass in the left breast E quadrant, fixed to the overlying skin. Serum CEA and CA15-3 levels were within the normal range (1.2 ng/mL and 12.6 U/mL, respectively), whereas PSA was markedly elevated to 194 ng/mL. Because of the patient’s diabetes mellitus, MRI-PET could not be performed; therefore, mammography, breast ultrasonography, bone scintigraphy, and non-contrast CT were conducted. -Mammography: A well-circumscribed, round mass was identified in the superior quadrant.-Ultrasonography: A well-circumscribed, smooth, heterogeneous hypoechoic mass measuring 37 × 31 × 24 mm was identified in the left subareolar region.-CT: Multiple enlarged lymph nodes were observed in the pelvic, iliac, para-aortic, and perirectal regions, together with prostatic enlargement and irregular margins, suggestive of PC with lymph node metastases. No suspicious lymph nodes were found in the breast region.-Bone scintigraphy: Multiple areas of abnormal uptake consistent with bone metastases were observed, involving the left sacroiliac joint, iliac wing, external iliac region, cervical to lumbar spine, left scapula, left ribs, and left ilium (Fig. 1).-Pathology and immunohistochemistry: Core needle biopsy of the left breast tumor revealed invasive ductal carcinoma, histological grade 1. Immunohistochemistry revealed ER and PgR positivity in >90% of tumor cells, HER2 (4B5) score 1+, and a Ki-67 labeling index of <10%. Based on these findings, the tumor was classified as luminal A-like BC. Additional immunohistochemical staining demonstrated positivity for CK7 and GATA3 and negativity for CK20. Furthermore, immunohistochemistry for PSA, AMACR, and NKX3.1 was uniformly negative, further supporting the diagnosis of primary BC rather than metastatic PC to the breast (Fig. 2). Nearly 100% of the tumor cells were positive for AR. -Mammography: A well-circumscribed, round mass was identified in the superior quadrant. Mammography: A well-circumscribed, round mass was identified in the superior quadrant. -Ultrasonography: A well-circumscribed, smooth, heterogeneous hypoechoic mass measuring 37 × 31 × 24 mm was identified in the left subareolar region. Ultrasonography: A well-circumscribed, smooth, heterogeneous hypoechoic mass measuring 37 × 31 × 24 mm was identified in the left subareolar region. -CT: Multiple enlarged lymph nodes were observed in the pelvic, iliac, para-aortic, and perirectal regions, together with prostatic enlargement and irregular margins, suggestive of PC with lymph node metastases. No suspicious lymph nodes were found in the breast region. CT: Multiple enlarged lymph nodes were observed in the pelvic, iliac, para-aortic, and perirectal regions, together with prostatic enlargement and irregular margins, suggestive of PC with lymph node metastases. No suspicious lymph nodes were found in the breast region. -Bone scintigraphy: Multiple areas of abnormal uptake consistent with bone metastases were observed, involving the left sacroiliac joint, iliac wing, external iliac region, cervical to lumbar spine, left scapula, left ribs, and left ilium (Fig. 1). Bone scintigraphy: Multiple areas of abnormal uptake consistent with bone metastases were observed, involving the left sacroiliac joint, iliac wing, external iliac region, cervical to lumbar spine, left scapula, left ribs, and left ilium (Fig. 1). -Pathology and immunohistochemistry: Core needle biopsy of the left breast tumor revealed invasive ductal carcinoma, histological grade 1. Immunohistochemistry revealed ER and PgR positivity in >90% of tumor cells, HER2 (4B5) score 1+, and a Ki-67 labeling index of <10%. Based on these findings, the tumor was classified as luminal A-like BC. Additional immunohistochemical staining demonstrated positivity for CK7 and GATA3 and negativity for CK20. Furthermore, immunohistochemistry for PSA, AMACR, and NKX3.1 was uniformly negative, further supporting the diagnosis of primary BC rather than metastatic PC to the breast (Fig. 2). Nearly 100% of the tumor cells were positive for AR. Pathology and immunohistochemistry: Core needle biopsy of the left breast tumor revealed invasive ductal carcinoma, histological grade 1. Immunohistochemistry revealed ER and PgR positivity in >90% of tumor cells, HER2 (4B5) score 1+, and a Ki-67 labeling index of <10%. Based on these findings, the tumor was classified as luminal A-like BC. Additional immunohistochemical staining demonstrated positivity for CK7 and GATA3 and negativity for CK20. Furthermore, immunohistochemistry for PSA, AMACR, and NKX3.1 was uniformly negative, further supporting the diagnosis of primary BC rather than metastatic PC to the breast (Fig. 2). Nearly 100% of the tumor cells were positive for AR. Bone scintigraphy showing multiple areas of increased radiotracer uptake (hot spots) in the scapula, ribs, thoracic and lumbar vertebrae, sacrum, pelvic bones, and femur, indicating extensive bone metastases. Representative immunohistochemical staining for (A) PSA, (B) AMACR, and (C) NKX3.1. Tumor cells were negative for all 3 markers, supporting the diagnosis of primary BC rather than breast metastasis from PC. Scale bars, 500 μm. Original magnification, ×10 (A–C). BC, breast cancer; PC, prostate cancer; PSA, prostate-specific antigen MRI-US fusion-guided prostate biopsy performed at another institution revealed adenocarcinoma with a Gleason score of 4 + 5 = 9, consistent with high-risk PC. -Clinical Course: The treatment strategy and staging were determined in collaboration with the urology department at another institution. The BC was clinically staged as cT2N0M0, corresponding to cStage IIA, whereas the PC with multiple bone metastases was classified as Stage IV. Although a bone biopsy was not performed, the clinical findings and pathological results supported the diagnosis of bone metastases originating from PC. Regarding the enlarged pelvic lymph nodes, PET could not be performed and a definitive diagnosis was not achieved; however, after discussion with the collaborating urologists, they were clinically judged to represent metastases from PC, and no biopsy was conducted. Clinical Course: The treatment strategy and staging were determined in collaboration with the urology department at another institution. The BC was clinically staged as cT2N0M0, corresponding to cStage IIA, whereas the PC with multiple bone metastases was classified as Stage IV. Although a bone biopsy was not performed, the clinical findings and pathological results supported the diagnosis of bone metastases originating from PC. Regarding the enlarged pelvic lymph nodes, PET could not be performed and a definitive diagnosis was not achieved; however, after discussion with the collaborating urologists, they were clinically judged to represent metastases from PC, and no biopsy was conducted. For male BC, genetic counseling regarding BRCA testing was offered, but the patient declined genetic testing. At the time of diagnosis, laboratory data showed no remarkable abnormalities, the patient’s general condition was good, and there was no significant pain from bone metastases. Although the BC was technically resectable and no evidence of regional lymph node involvement was observed, the urgency for surgery was considered low. Because the prognosis was primarily determined by PC, treatment for PC was prioritized, and ADT was initiated. In this case, ADT consisted of contemporary total androgen blockade with a GnRH antagonist plus an AR antagonist. At 6 months after initiation of therapy, laboratory tests showed CEA 1.9 ng/mL and CA15-3 10.9 U/mL, both within normal limits, while PSA had decreased to 3.19 ng/mL. CT scan demonstrated shrinkage of the prostate and regression of the enlarged pelvic lymph nodes. Notably, marked shrinkage of the breast tumor was also confirmed (Fig. 3). As the patient remained in good general condition and both tumors were controlled, breast surgery was reconsidered in consultation with the urology department, and approximately 6 months after starting ADT, a mastectomy with sentinel lymph node biopsy was performed. The breast tumor measured 37 mm radiologically before ADT and 12 mm pathologically in the surgical specimen, accompanied by fibrosis and histiocytic infiltration. The chronological clinical course, including ADT administration, serial tumor marker measurements, radiologic response, and surgical intervention, is summarized in Fig. 4. The pathological therapeutic effect was grade 1b. No metastasis was identified in the sentinel lymph nodes. The tumor was classified as ypT1c pN0, consistent with a non-pathological complete response. Hematoxylin and eosin staining of the surgical specimen revealed residual invasive carcinoma and DCIS (Fig. 5). The presence of residual invasive carcinoma and DCIS strongly supported the diagnosis of primary breast carcinoma rather than metastatic PC. Mammography, US, and non-contrast CT images of the left breast. The upper panels show a round, well-defined mass on mammography, an oval, well-circumscribed mixed-echoic mass on US, and a localized subareolar mass on CT. The lower panels show follow-up images obtained 6 months later, demonstrating a reduction in tumor size. Scale bars are included in each panel. The mammography scale bar represents approximately 5 cm, while the US and CT images display scales in centimeters. Chronological clinical course of the patient. Serum PSA levels and breast tumor size are shown over the course of ADT. PSA decreased from 194 ng/mL at baseline to 3.19 ng/mL after 6 months of ADT. The breast tumor decreased from 37 mm on pretreatment imaging to 12 mm on pathological examination of the surgical specimen. Breast surgery was performed after 6 months of ADT. ADT, androgen deprivation therapy; PSA, prostate-specific antigen Low-power view of hematoxylin and eosin staining of the surgical specimen showing DCIS and invasive carcinoma within the stroma. Original magnification, ×4. DCIS, ductal carcinoma in situ Additional immunohistochemical analysis of the surgical specimen demonstrated ER positivity in >90% of tumor cells, PgR positivity in 30%, HER2 score 0, a Ki-67 labeling index of <5%, and AR positivity in 70% of tumor cells. A comparison of the immunohistochemical findings before and after ADT is shown in Fig. 6. Comparison of histopathological and immunohistochemical findings before and after ADT. Representative H&E and immunohistochemical findings are shown. (A–C) Pretreatment core needle biopsy specimen. (D–F) Surgical specimen obtained after 6 months of ADT. (A, D) H&E staining. (B, E) ER. (C, F) AR. Scale bars, 500 μm (A–C) and 100 μm (D–F). Original magnification, ×10 (A–C) and ×20 (D–F). ADT, androgen deprivation therapy; AR, androgen receptor; ER, estrogen receptor; H&E, hematoxylin and eosin For postoperative adjuvant therapy in ER-positive male BC, tamoxifen is generally recommended. However, in this case, because the tumor had already been controlled by ADT and prognosis was determined by PC, no additional treatment for BC was considered necessary. The patient has remained under follow-up while continuing ADT for PC. Unfortunately, detailed information on the course of PC treatment is limited, as management was performed at another institution. DISCUSSION Synchronous occurrence of male BC and PC is extremely rare, and no standard treatment strategies have been established. Because of the paucity of cases, clinical trials specifically targeting male BC have not been conducted, and treatment is generally based on guidelines for female BC.2) When treating synchronous malignancies, priority is usually given to the cancer with the greater prognostic impact. In previously reported cases of synchronous operable male BC and PC, the conventional approach involved surgical management of early-stage BC for local control, followed by ADT for PC.3–5) The details of previously reported cases are summarized in Table 1. Table 1Reported cases of synchronous male BC and PC in which ADT was utilizedBreast subtypeBreast stageProstate stageTreatment sequenceProstate therapyBC response to ADTCheng 20243)ER+PgR+HER2-cStage IIARecurrent PCBC surgery to ADTADTNot applicableOmata 20094)ER+PgR+HER2-cStage IIAStage IVBC surgery to ADTADTNot applicableTamaki 20095)ER+PgR+HER2-cStage IIAcStage IIBC developed during ADTADTNot applicablePresent caseER+PgR+AR+HER2-cStage IIAStage IVBC surgery after ADT initiationADTYesSummary of previously reported cases of synchronous male BC and PC treated with ADT.ADT, androgen deprivation therapy; BC, breast cancer; PC, prostate cancer Reported cases of synchronous male BC and PC in which ADT was utilized Summary of previously reported cases of synchronous male BC and PC treated with ADT. ADT, androgen deprivation therapy; BC, breast cancer; PC, prostate cancer Some reports have described male BC arising during ADT for PC, but no tumor regression was observed. For instance, in the case reported by Tamaki et al.,5) BC developed during ADT for PC, and breast surgery was subsequently performed. To the best of our knowledge, our case represents one of the few reported cases in which contemporary ADT controlled both metastatic PC and synchronous operable ER- and AR-positive male BC without upfront breast surgery. In our case, after consultation with urologists at another institution, metastatic PC was prioritized, and ADT was initiated before breast surgery. Additional endocrine therapy with tamoxifen was not introduced because suppression of gonadal function by the GnRH antagonist was expected to reduce circulating estrogen levels. Furthermore, the BC was considered operable, and surgery rather than neoadjuvant endocrine therapy would ordinarily have been the standard treatment. Interestingly, regression of the BC was observed during the course of ADT. ADT is the standard treatment for metastatic PC, and previous reports have also shown its activity in male BC, particularly in ER- and AR-positive tumors, making it a rational therapeutic approach in synchronous malignancies. Previous studies, including the classical report by Lopez et al., demonstrated that total androgen blockade with a GnRH agonist and antiandrogen could induce tumor regression in metastatic male BC, with a response rate of 64%, including 2 complete responses, highlighting the hormone dependency of this disease.6) However, those studies exclusively addressed inoperable or metastatic cases. Unlike metastatic male BC, where experimental endocrine strategies such as ADT may be considered due to limited options, operable cases are generally managed according to guidelines for female BC, with upfront surgery followed by adjuvant therapy. A previous case report has described regression of male BC in the setting of synchronous PC and metastatic male BC treated with an LHRH agonist alone.7) However, in that report, the BC was inoperable and treatment was limited to systemic therapy. In contrast, our case demonstrates that contemporary standard ADT—comprising a GnRH antagonist and an AR antagonist—simultaneously controlled both metastatic PC and synchronous, operable ER- and AR-positive male BC. This finding suggests that modern ADT may represent a rational initial treatment strategy, potentially as an alternative to upfront surgery, in the management of synchronous PC and male BC. Possible mechanisms by which ADT may have contributed to BC control in this case include: 1)Suppression of peripheral estrogen production through gonadotropin inhibition with a GnRH antagonist, leading to reduced ER signaling. Suppression of peripheral estrogen production through gonadotropin inhibition with a GnRH antagonist, leading to reduced ER signaling. 2)Direct blockade of tumor growth signals through inhibition of AR-driven pathways. Direct blockade of tumor growth signals through inhibition of AR-driven pathways. 3)Modulation of ER–AR crosstalk, whereby endocrine therapy may disrupt the interplay between androgen and estrogen signaling pathways. Modulation of ER–AR crosstalk, whereby endocrine therapy may disrupt the interplay between androgen and estrogen signaling pathways. With respect to the first mechanism, suppression of gonadotropin secretion by GnRH antagonists reduces gonadal androgen production. Because circulating estrogens in men are largely derived from peripheral aromatization of androgens, this may lead to a reduction in estrogen levels and subsequent attenuation of ER-mediated proliferative signaling. Therefore, reduction of estrogen levels induced by GnRH antagonists may have contributed to tumor regression in the present case.8) Given the strongly ER-positive (>90%) luminal A-like phenotype of the tumor, attenuation of ER-mediated signaling through estrogen depletion may have played a substantial role in the observed therapeutic response. Regarding the second mechanism, AR blockade may also have contributed to tumor control, although its relative contribution compared with estrogen depletion remains uncertain. Clinical evidence supporting AR antagonists in BC remains limited but is evolving. Early-phase clinical trials in AR-positive, ER-negative BC, particularly within subsets of TNBC, have demonstrated proof of concept for AR-targeted therapy, with clinical benefit observed in a proportion of patients.9) More recent studies suggest that the effects of AR antagonists may depend on tumor biology, particularly the balance between AR and ER signaling. Experimental studies have shown that AR blockade can suppress proliferation of AR-positive BC cells and may influence both androgen- and estrogen-related signaling through ER–AR crosstalk. However, the precise role of AR signaling in BC remains incompletely understood.10–12) Interestingly, in contrast to studies evaluating AR antagonists, recent clinical evidence has also demonstrated clinical activity of AR agonists in selected subtypes of BC. A phase II study of the selective AR modulator enobosarm demonstrated clinical benefit in patients with AR-positive, ER-positive, and HER2-negative advanced BC, with treatment response correlating with AR expression levels.13) These findings suggest that AR signaling may influence treatment response in a subset of BCs. However, the apparently conflicting clinical activity observed with both AR antagonists and AR agonists in BC highlights the complexity of AR biology, and its precise role remains incompletely understood. Regarding the third mechanism, accumulating evidence suggests that AR can modulate ER transcriptional activity in ER- and AR-positive BC in a context-dependent manner. Mechanistically, AR has been shown to competitively bind to estrogen response elements, displacing ER from chromatin and thereby suppressing ER-driven transcription, while also regulating ERα signaling through multiple pathways.14) However, the present case was treated with an AR antagonist, and it remains unclear whether these mechanisms are directly applicable to male BC. The unique endocrine milieu of male patients may result in biological responses that differ from those observed in female BC. Additional immunohistochemical analysis of the surgical specimen demonstrated persistent ER expression (>90%), decreased PgR expression (30%), a HER2 score of 0, a low Ki-67 labeling index (<5%), and reduced but persistent AR positivity (70%). Compared with the pretreatment core needle biopsy, AR expression decreased from nearly 100% to 70% after ADT, while ER expression remained strongly positive. Although intratumoral heterogeneity cannot be excluded, these findings raise the possibility that ADT altered hormone receptor expression in the tumor. Whether these immunophenotypic changes reflect a biological effect of androgen deprivation or the selective survival of specific tumor cell populations remains unclear and warrants further investigation. Importantly, all of the above clinical and preclinical data are based on female BC, and their applicability to male BC remains uncertain. Given the markedly different endocrine environment between men and women, male BC likely has a distinct biological background. However, owing to the rarity of male BC, no clinical studies have directly addressed this issue. Our case has several limitations. Detailed information regarding PC treatment was limited, as management was performed at another institution, and this is a single case report, precluding generalization. In the present case, ADT was initiated before surgery for synchronous operable male BC and metastatic PC, resulting in regression of both malignancies. This case suggests that, in the unique clinical setting in which prognosis is primarily determined by Stage IV PC, ADT may exert meaningful antitumor activity against operable ER- and AR-positive male BC. Therefore, an initial surgery-sparing approach with ADT may represent a reasonable therapeutic option in selected patients with synchronous malignancies, particularly when general anesthesia carries substantial risk or when surgery can be safely deferred. CONCLUSIONS This case represents an extremely rare instance of synchronous operable male BC and metastatic PC. Upfront ADT resulted in regression of both malignancies. These findings suggest that ADT may represent a reasonable initial treatment option in selected patients with synchronous malignancies, particularly when general anesthesia carries substantial risk or when surgery can be safely deferred.